

Mauna Kea Technologies Announces the Transfer of its Shares on the Euronext Growth Paris Market Will Be Effective August 8, 2023

Paris and Boston, August 4, 2023 – 8:00 a.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio[®], the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that the transfer of its ordinary shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility will be effective on August 8, 2023.

The application for admission of Mauna Kea Technologies ordinary shares to the Euronext Growth Paris market was approved by the Euronext Admissions Committee at its meeting on August 3, 2023.

This transfer, which was authorized by the General Meeting of Mauna Kea Technologies shareholders held on June 2, 2023, will enable the Company to be listed on a market offering a flexible regulatory framework tailored to its size and market capitalization, while reducing certain operating constraints specific to the Euronext Paris market. The transfer to Euronext Growth Paris should also simplify the Company's operations and reduce the costs associated with its listing, while enabling it to continue to benefit from the advantages of the financial markets.

Mauna Kea Technologies will continue to deliver accurate, precise and truthful information, disclosing any insider information concerning the Company, in accordance with the provisions of Regulation (EU) No. 596/2014 of April 16th, 2014 on market abuse ("MAR").

The Information Document drawn up in connection with this transfer is available on the Company's website (<https://www.maunakeatech.com>) under the "Investors" section.

The ISIN code for Mauna Kea Technologies shares remains unchanged (FR0010609263), and the mnemonic code becomes ALMKT. Mauna Kea Technologies shares remain eligible for the PEA-PME scheme.

The operation was performed with Allegra Finance as the listing sponsor.

Definitive timetable:

August 3, 2023	Notification by Euronext of the decision to list the shares on Euronext Growth Paris
August 4, 2023	Publication of a Euronext market notice announcing the delisting of Mauna Kea Technologies' ordinary shares (MKEA) from Euronext Paris Publication of a Euronext market notice announcing the listing of Mauna Kea Technologies' ordinary shares (ALMKT) on Euronext Growth Paris Publication of a press release by the Company and of the Information Document on the Company's and Euronext's websites
August 8, 2023	Effective transfer: delisting of Mauna Kea Technologies shares from Euronext Paris (before market opening) and listing of Mauna Kea Technologies shares on Euronext Growth Paris (at market opening) - first listing

Next financial release:

Financial results for the first half of 2023, on September 28th, 2023 before market opening.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

Mauna Kea Technologies - Investor Relations

investors@maunakeatech.com

NewCap - Investor Relations

Aurélie Manavarere / Thomas Grojean

+33 (0)1 44 71 94 94

maunakea@newcap.eu

Disclaimer

This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 3 of Mauna Kea Technologies' 2022 Universal Registration Document filed with the Autorité des marchés financiers (AMF) on June 28, 2023 under number D-23-0545, which is available on the Company's website (www.maunakeatech.com), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently



consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.